Operationalise an EAP for a rare neurodegenerative condition (ALS)
READ MORE
We are committed to ensuring patients are considered as a true partner in the clinical development pathway, working together with patient groups to gather insights and incorporate the patient and family voice, from design to delivery of all of our Clinical Trials and Early Access Programs.
Early, often and transparent patient engagement is a crucial part of clinical development. Considering the patient perspective and incorporating the insights from the patient community can improve feasibility, accelerate timelines to approval and reduce patient and family burden. We listen and learn to truly understand a patient’s condition, their unique, personal experience and specific needs before we begin.
Along with our global Patient Advocacy team, we can support all stages of the clinical development pathway, from preclinical phase to commercialization. Through early, often and transparent engagement with the patient community, the team fosters positive and mutually beneficial relationships.
Our established partnerships with patient advocacy groups uniquely position us to collaboratively deliver patient centric Clinical Trials and Early Access Programs. Here are some of the activities that we are responsible for:
In response to the patient community, we have created educational materials to support the understanding of the Clinical Trials and Early Access Programs. You can find more information and access these resources within our Press section.